Co-Diagnostics, Inc.

CODX

US1897631057

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
1.35 ^USD	+3.85%		+8.00%	+1.50%

Jul. 02	Co-Diagnostics Expands Vector Control Customer Base	MT
Jul. 02	Co-Diagnostics, Inc. Expands Vector Control Customer Base to 25 Customers Across 15 U.S. States	CI

Co-Diagnostics, Inc. Provides Earnings Guidance for the Fourth Quarter of 2020

January 06, 2021 at 09:30 am EST

Co-Diagnostics, Inc. provided earnings guidance for the fourth quarter of 2020. For the quarter the company expected revenue is anticipated to be in the range from $24 million to $25.98 million.

Latest news about Co-Diagnostics, Inc.

Co-Diagnostics Expands Vector Control Customer Base	Jul. 02	MT
Co-Diagnostics, Inc. Expands Vector Control Customer Base to 25 Customers Across 15 U.S. States	Jul. 02	CI
Co-Diagnostics, Inc. Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform	Jun. 14	CI
HC Wainwright Adjusts Price Target on Co-Diagnostics to $2 From $2.50, Maintains Neutral Rating	May. 13	MT
Transcript : Co-Diagnostics, Inc., Q1 2024 Earnings Call, May 09, 2024	May. 09
Co-Diagnostics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Co-Diagnostics, Inc. Inaugurates New Manufacturing Facility in Utah with Ribbon Cutting Event	Apr. 12	CI
Co-Diagnostics, Inc. Appoints Executive Appointments	Apr. 04	CI
Co-Diagnostics, Inc. Appoints Richard Abbott as President	Mar. 15	CI
Transcript : Co-Diagnostics, Inc., Q4 2023 Earnings Call, Mar 14, 2024	Mar. 14
Tranche Update on Co-Diagnostics, Inc.'s Equity Buyback Plan announced on March 15, 2022.	Mar. 14	CI
Co-Diagnostics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Co-Diagnostics Gets Approval From India's Central Drugs Standard Control Organization For Manufacturing, Sale of Influenza Multiplex Test	Mar. 07	MT
Co-Diagnostics Submits PCR COVID-19 Test and PCR Pro Instrument for FDA Review	Dec. 27	MT
Co-Diagnostics Shares Rise 21% After Submitting FDA Application For Covid-19 Test Platform	Dec. 27	DJ
Co-Diagnostics, Inc. Completes Submission to FDA for Co-Dx PCR Pro	Dec. 27	CI
HC Wainwright Adjusts Price Target on Co-Diagnostics to $3 From $2, Maintains Neutral Rating	Nov. 13	MT
Transcript : Co-Diagnostics, Inc., Q3 2023 Earnings Call, Nov 09, 2023	Nov. 09
Earnings Flash (CODX) CO-DIAGNOSTICS Reports Q3 Revenue $2.5M	Nov. 09	MT
Tranche Update on Co-Diagnostics, Inc.'s Equity Buyback Plan announced on March 15, 2022.	Nov. 09	CI
Co-Diagnostics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Co-Diagnostics, Inc.(NasdaqCM:CODX) dropped from S&P Global BMI Index	23-09-18	CI
Co-Diagnostics, Inc. Appoints Ivory Chang as Chief Regulatory Affairs Officer	23-08-29	CI
HC Wainwright Adjusts Price Target on Co-Diagnostics to $2 From $3, Keeps Neutral Rating	23-08-14	MT
Transcript : Co-Diagnostics, Inc., Q2 2023 Earnings Call, Aug 10, 2023	23-08-10

Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Companyâs technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the userâs mobile device.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Co-Diagnostics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

1.35 USD

Average target price

2 USD

Spread / Average Target

+48.15%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Diagnostic & Testing Equipment

	1st Jan change	Capi.
CO-DIAGNOSTICS, INC.	+1.50%	42.23M
SARTORIUS AG	-27.91%	16.33B
QUIDELORTHO CORPORATION	-56.07%	2.17B
INNER MONGOLIA FURUI MEDICAL SCIENCE CO., LTD.	+19.09%	1.88B
SHANGHAI MICROPORT EP MEDTECH CO., LTD.	-12.63%	1.45B
BIOTAGE AB	+29.99%	1.32B
REVENIO GROUP OYJ	+8.32%	853M
SHANGHAI AOHUA PHOTOELECTRICITY ENDOSCOPE CO., LTD.	-30.60%	799M
CONTEC MEDICAL SYSTEMS CO.,LTD	-36.50%	726M
CELLAVISION AB	+29.48%	622M

Medical Diagnostic & Testing Equipment